AstraZeneca shares drop 7% after report on $400 billion merger talks with Bristol Myers Squibb
· cnbc.com
The companies have discussed a potential merger over several months, the Financial Times reported on Sunday.
AstraZeneca shares dropped as much as 7% after a report that the U.K.'s largest drugmaker was in talks with U.S. peer Bristol Myers Squibb over a megadeal that,...